Hemodialysis as an alternative treatment of mexiletine intoxication

被引:11
作者
Akinci, Emine [1 ]
Yuzbasioglu, Yucel [1 ]
Coskun, Figen [1 ]
机构
[1] Ankara Res & Training Hosp, Emergency Dept, Ankara, Turkey
关键词
NEUROPATHIC PAIN; PHARMACOKINETICS; TOCAINIDE; OVERDOSE;
D O I
10.1016/j.ajem.2010.08.027
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Mexiletine is a class IB antiarrhythmic agent. Although it is primarily used in treating ventricular arrhythmias, recent indications for use of mexiletine include chronic and neuropathic pains. At high doses, mexiletine causes drowsiness, confusion, nausea, hypotension, sinus bradycardia, paresthesia, seizures, bundle branch block, atrioventricular heart block, ventricular arrhythmias, asystole, cardiovascular collapse, and coma. A 23-year-old male patient presented to the emergency department with intentional ingestion of high-dose mexiletine. Despite decontamination and supportive treatment, his vitals deteriorated during the observation period; and he developed stupor and dysarthria. Patient then underwent hemodialysis. His vital signs and overall condition improved rapidly following hemodialysis treatment. In this case report, we aimed to emphasize hemodialysis as a useful alternative therapy for severe mexiletine intoxications.
引用
收藏
页码:1235.e5 / 1235.e6
页数:2
相关论文
共 14 条
[1]  
CAMPBELL RWF, 1987, NEW ENGL J MED, V316, P29
[2]   POISONING DUE TO CLASS-1B ANTIARRHYTHMIC DRUGS - LIGNOCAINE, MEXILETINE AND TOCAINIDE [J].
DENARO, CP ;
BENOWITZ, NL .
MEDICAL TOXICOLOGY AND ADVERSE DRUG EXPERIENCE, 1989, 4 (06) :412-428
[3]   Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats [J].
Egashira, Nobuaki ;
Hirakawa, Shingo ;
Kawashiri, Takehiro ;
Yano, Takahisa ;
Ikesue, Hiroaki ;
Oishi, Ryozo .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 (04) :473-476
[4]  
ELLENHORN M, 1997, ELLENHORNS MED TOXIC, P498
[5]  
JEQUIER P, 1976, LANCET, V1, P429
[6]   A MEXILETINE INTOXICATION [J].
KEMPTON, J ;
MANOUKIAN, A ;
LEVINE, B ;
SMIALEK, J .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1994, 18 (06) :346-347
[7]   Clinical pharmacokinetics of mexiletine [J].
Labbé, L ;
Turgeon, J .
CLINICAL PHARMACOKINETICS, 1999, 37 (05) :361-384
[8]   Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1 [J].
Logigian, E. L. ;
Martens, W. B. ;
Moxley, R. T. ;
McDermott, M. P. ;
Dilek, N. ;
Wiegner, A. W. ;
Pearson, A. T. ;
Barbieri, C. A. ;
Annis, C. L. ;
Thornton, C. A. ;
Moxley, R. T., III .
NEUROLOGY, 2010, 74 (18) :1441-1448
[9]   Effects of Mexiletine, a CYP1A2 Inhibitor, on Tizanidine Pharmacokinetics and Pharmacodynamics [J].
Momo, Kenji ;
Homma, Masato ;
Osaka, Yoshiko ;
Inomata, Shin-ichi ;
Tanaka, Makoto ;
Kohda, Yukinao .
JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (03) :331-337
[10]   Treatment of Neuropathic Pain: An Overview of Recent Guidelines [J].
O'Connor, Alec B. ;
Dworkin, Robert H. .
AMERICAN JOURNAL OF MEDICINE, 2009, 122 (10) :S22-S32